ATECT

Advanced T-cell Engineered for Cancer Therapy

Coordinatore	UNIVERSITY COLLEGE LONDON    more  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Mr. Nome: Martin Cognome: Scott Email: send email Telefono: 442031000000
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://atect-fp7.org
Totale costo	7˙780˙342 €
EC contributo	5˙931˙151 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-12-01   -   2018-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Mr. Nome: Martin Cognome: Scott Email: send email Telefono: 442031000000	UK (LONDON)	coordinator	2˙646˙887.00
2	CELLECTIS SA  Organization address address: RUE JEAN ANTOINE DE BAIF 12 city: PARIS postcode: 75013 contact info Titolo: Dr. Nome: Julianne Cognome: Smith Email: send email Telefono: +33 181691618 Fax: +33 181691601	FR (PARIS)	participant	1˙448˙140.00
3	STICHTING HET NEDERLANDS KANKER INSTITUUT  Organization address address: PLESMANLAAN 121 city: AMSTERDAM postcode: 1066 CX contact info Titolo: Dr. Nome: Henri Cognome: Van Luenen Email: send email Telefono: 31205122097	NL (AMSTERDAM)	participant	640˙980.00
4	PHILOGEN SPA  Organization address address: PIAZZA LA LIZZA 7 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Laura Cognome: Baldi Email: send email Telefono: +39 057717816 Fax: 395772000000	IT (SIENA)	participant	625˙900.00
5	UNIVERSITAET ZUERICH  Organization address address: Raemistrasse 71 city: ZURICH postcode: 8006 contact info Titolo: Dr. Nome: Burkhard Cognome: Becher Email: send email Telefono: +41 44 6353703 Fax: +41 44 6344901	CH (ZURICH)	participant	569˙244.00
6	CELLECTICS THERAPEUTICS SAS  Organization address address: RUE DE LA CROIX DE JARRY 8 city: PARIS postcode: 75013 contact info Titolo: Dr. Nome: Julianne Cognome: Smith Email: send email Telefono: +33 181691618 Fax: +33 181691601	FR (PARIS)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'T-cell engineering strategies for Cancer therapy, either Chimeric Antigen Receptors (CARs) or TCR transfer holds promise to revolutionize cancer treatment. There are, however, considerable barriers to be overcome to take this form of therapy to a format that can benefit all EU citizens with a wide range of common cancers. The aim of this consortium is to exploit advances in T-cell engineering to allow the full potential of CAR therapy to be unleashed. At present, CAR therapy requires a bespoke autologous therapeutic product for each patient. This greatly limits practicality, scalability and commercialisation. The development of a strategy for creation of universal engineered T-cells is the first key aim of this consortium. There is an increased appreciation of the immunological hostilities (CAR) T-cells face in the tumour microenvironment, and prevention of this local immune suppressive effect will likely be critical in permitting effective tumour control. The second main aim of this proposal is therefore to engineer CAR T-cells to be resistant to the hostile microenvironment. CAR T-cells can only be effective if they can access the tumour site. Exploiting the fact that neo-angiogenesis is a hallmark of neoplastic progression, the third aim of the consortium is to utilise endothelial cues of neo-angiogenesis to direct CAR T-cell migration and activity. The central technological theme of this consortium is the application of TALEN-mediated gene editing strategies alongside genetic modification with integrating vectors. Using this approach, we will implement a clinical study of “universal” CAR T-cells in refractory lymphoma. Further, this work will be complemented with highly focused development of T-cells which are resistant to hostile microenvironments and which can home to sites of neovascularization. The legacy this consortium wishes is commercialization of universal CAR therapy for a broad swathe of human cancers.'